Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model.

MLA

Bergman, Daniel R., et al. “Dysregulated FGFR3 Signaling Alters the Immune Landscape in Bladder Cancer and Presents Therapeutic Possibilities in an Agent-Based Model.” Frontiers in Immunology, vol. 15, Mar. 2024, p. 1358019. EBSCOhost, https://doi.org/10.3389/fimmu.2024.1358019.

APA

Bergman, D. R., Wang, Y., Trujillo, E., Fernald, A. A., Li, L., Pearson, A. T., Sweis, R. F., & Jackson, T. L. (2024). Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model. Frontiers in Immunology, 15, 1358019. https://doi.org/10.3389/fimmu.2024.1358019

Chicago

Bergman, Daniel R, Yixuan Wang, Erica Trujillo, Anthony A Fernald, Lie Li, Alexander T Pearson, Randy F Sweis, and Trachette L Jackson. 2024. “Dysregulated FGFR3 Signaling Alters the Immune Landscape in Bladder Cancer and Presents Therapeutic Possibilities in an Agent-Based Model.” Frontiers in Immunology 15 (March): 1358019. doi:10.3389/fimmu.2024.1358019.